January 16, 2026 4:47pm

For all my … <some say> … RANTINGS, I say TRUTH … closed Friday closed up =$o.31 <look at the volume 974,340 shares trading <”someone’s” covering downslide (?) having closed down Tursday -$0.75 or -3.03% with 1.586 M shares traded after Wednesday $0.00 <was as low as -$0.45> afterTuesday +$0.28 <opened  -$0.26) after Monday UP +$0.67 after being DOWN on Friday -$1.71 or -6.99%  after Thursday's -$0.76 or -2.89% to $25.55 after Wednesday (1/7) was UP +$0.18 ...

I believe their I Banks are executing the “PUMP” to protect the offering share pricing after being stripped of value in past sessions. DON’T be distracted – CONTINUE the SELL into strength, right yet again, let's NOT be a set-up for a PONZI schematic? Continuous declines are here soon to stay; timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall!

STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals.

Don't be swayed by incremental positive swings, a blunderbuss effect will cause a swarf lacking in subtlety

Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!

  • CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
  • It has begun; timing will be everything!
  • The higher CAPR rises, the steeper the fall!

I also BELIEVE that the CEO forgot investors in delivering the announcement of P3 HOPE-3 study; letting the investment bankers know first as how quickly a public offering “evolved”?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.